Enabling precision medicine with AI-driven interpretation
For all NGS testing from whole genomes and exomes to targeted panels
Fabric Genomics offers the leading AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing with best-in-class accuracy and scalability.
Dozens of the worlds leading hospitals, clinical labs, and academic centers such as Cincinnati Children’s, InterMountain, Rady Children’s Institute, LabCorp, and others count on Fabric AI technology and Fabric’s clinical services for their complete NGS software and services needs.
Why Fabric?
Accuracy &
Diagnostic Yield
Diagnostic Yield
- 98% of causal variants ranked in the top 5 by GEM for rare disease
- ACMG-compliant classification backed by validation across
> 50,000 variants
Scalability
& Efficiency
& Efficiency
- 10 times more cases with the same team
- Average clinical review time of 15min for WGS
- Optimized workflow for efficient throughput, secure, API integration with LIMS & EMR
Comprehensive Software
& Services
& Services
- Get up and running in as little as 4 weeks
- Software Set up & Lab Validation
- Panel curation and SOP design
- Interpretation and signout
Leadership
Martin Reese, Ph.D.
Co-Founder, President, and CEO
A recognized leader in genomics and bioinformatics, Dr. Reese has co-founded and helped build three influential companies in the field – Neomorphic, IDbyDNA, and Fabric Genomics.
At Neomorphic, he developed genome annotation software that enabled Affymetrix’s successful commercialization of microarray technology. He went on to launch IDbyDNA, a spinout from ARUP Laboratories, where he led the creation of the first real-time, web-based pathogen interpretation platform; the company was acquired by Illumina in 2022. Dr. Reese has also played a key role in collaborative efforts to advance genome annotation, contributing to the Berkeley Drosophila Genome Project and developing gene-finding algorithms in support of the Human Genome Project. He holds a master’s degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly awarded by the University of Hohenheim, Germany, and the University of California, Berkeley.
His work has been instrumental in advancing genome annotation, machine learning in genomics, and the broader field of precision medicine.
Martin Reese, PhD.
Co-Founder, President, Board Member, and CEO
Martin Reese, Ph.D.
Co-Founder, President, and CEO
A recognized leader in genomics and bioinformatics, Dr. Reese has co-founded and helped build three influential companies in the field – Neomorphic, IDbyDNA, and Fabric Genomics.
At Neomorphic, he developed genome annotation software that enabled Affymetrix’s successful commercialization of microarray technology. He went on to launch IDbyDNA, a spinout from ARUP Laboratories, where he led the creation of the first real-time, web-based pathogen interpretation platform; the company was acquired by Illumina in 2022. Dr. Reese has also played a key role in collaborative efforts to advance genome annotation, contributing to the Berkeley Drosophila Genome Project and developing gene-finding algorithms in support of the Human Genome Project. He holds a master’s degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly awarded by the University of Hohenheim, Germany, and the University of California, Berkeley.
His work has been instrumental in advancing genome annotation, machine learning in genomics, and the broader field of precision medicine.
Read more
Paul Billings, M.D., Ph.D.
Co-Founder and Acting Chief Medical Officer
Dr. Billings serves as Chief Medical Officer at Fabric Genomics. Prior to joining Fabric Genomics, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation. Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. He was Deputy Chief of Staff and Chief of General Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at UC Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings received an A.B. summa cum laude from UC San Diego, and both his M.D. and Ph.D. degrees from Harvard University.
Paul Billings, M.D., PhD.
Co-Founder & Acting Chief Medical Officer
Paul Billings, M.D., Ph.D.
Co-Founder and Acting Chief Medical Officer
Dr. Billings serves as Chief Medical Officer at Fabric Genomics. Prior to joining Fabric Genomics, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation. Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. He was Deputy Chief of Staff and Chief of General Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at UC Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings received an A.B. summa cum laude from UC San Diego, and both his M.D. and Ph.D. degrees from Harvard University.
Read more
Erwin Frise, PhD.
Vice President of Technology and Data ScienceÂ
Erwin Frise, Ph.D.
VP, Technology and Data Science
Dr. Frise serves as VP, Technology and Data Science. Prior to joining Fabric, Erwin was a PI at the Berkeley Drosophila Genome Project at Lawrence Berkeley National Laboratories. Working closely with the statistics department at UC Berkeley, he pioneered new methods for low dimensional statistical representations for high dimensional data, image analysis and microscope automation. Earlier he was instrumental for the annotation of the first metazoan genome (Drosophila) by contributing analysis algorithms and developing one of the first high performance compute clusters for biological genome annotation.
Dr. Frise holds a Masters degree in Molecular Biology and a Ph.D. in Genetics jointly from University of Vienna, Austria and the University of California, San Francisco.
Read more
Russell Nofsinger
Vice President of Genomic Medicine
Vanisha Mistry
Vice President of Customer Success
Vanisha serves as Vice President of Customer Success focusing on ensuring that customers achieve their desired outcomes whilst using Fabric, driving customer satisfaction, retention, and growth. Before joining Fabric Genomics, Vanisha held an analyst position at Genomics England, testing the services offered by the interpretation partners and contributing to the analysis pipeline. At Fabric she supported the implementation of the Fabric software at Genomics England and led all support and training activities. She held a postdoctoral research position at the University of Cambridge in Sadaf Farooqi’s lab, performing research into early-onset obesity, alongside researchers at the well-renowned Sanger Institute. She completed her PhD under David Van Heel at Queen Mary University of London, a pioneer in discovering the genetic basis of common autoimmune diseases. Vanisha holds a Master’s Degree in Forensic Genetics, obtained at University of Central Lancashire, and a Bachelor’s in Science in Forensic Science obtained at Nottingham Trent University.
Vanisha Mistry, PhD.
Vice President of Customer Success
Vanisha Mistry
Vice President of Customer Success
Vanisha serves as Vice President of Customer Success focusing on ensuring that customers achieve their desired outcomes whilst using Fabric, driving customer satisfaction, retention, and growth. Before joining Fabric Genomics, Vanisha held an analyst position at Genomics England, testing the services offered by the interpretation partners and contributing to the analysis pipeline. At Fabric she supported the implementation of the Fabric software at Genomics England and led all support and training activities. She held a postdoctoral research position at the University of Cambridge in Sadaf Farooqi’s lab, performing research into early-onset obesity, alongside researchers at the well-renowned Sanger Institute. She completed her PhD under David Van Heel at Queen Mary University of London, a pioneer in discovering the genetic basis of common autoimmune diseases. Vanisha holds a Master’s Degree in Forensic Genetics, obtained at University of Central Lancashire, and a Bachelor’s in Science in Forensic Science obtained at Nottingham Trent University.
Read more
Sam Strom
Vice President of Clinical Operations and Clinical Genetics
Dr. Strom serves as VP, Clinical Operations and Clinical Genetics at Fabric. Prior to joining Fabric, Sam served as a laboratory director at UCLA (Department of Pathology and Laboratory Medicine) and Fulgent Genetics, and as a Principal Scientist at Illumina.
Throughout his career, he has been at the forefront of translating raw genomic data into meaningful results for patients. He has made research contributions across various clinical areas, including rare and undiagnosed genetic disorders, degenerative eye disorders, and Parkinson’s disease. With end-to-end experience in pipeline design, variant caller development, and the evaluation of AI-based candidate prioritization, Sam is strongly positioned to lead the interpretation and reporting team at Fabric.
Dr. Strom holds a PhD in Human Genetics from UCLA and is board certified in Clinical Molecular Genetics by the American Board of Medical Genetics.
Sam Strom, PhD. FACMG
Vice President of Clinical Operations and Clinical Genomics
Sam Strom
Vice President of Clinical Operations and Clinical Genetics
Dr. Strom serves as VP, Clinical Operations and Clinical Genetics at Fabric. Prior to joining Fabric, Sam served as a laboratory director at UCLA (Department of Pathology and Laboratory Medicine) and Fulgent Genetics, and as a Principal Scientist at Illumina.
Throughout his career, he has been at the forefront of translating raw genomic data into meaningful results for patients. He has made research contributions across various clinical areas, including rare and undiagnosed genetic disorders, degenerative eye disorders, and Parkinson’s disease. With end-to-end experience in pipeline design, variant caller development, and the evaluation of AI-based candidate prioritization, Sam is strongly positioned to lead the interpretation and reporting team at Fabric.
Dr. Strom holds a PhD in Human Genetics from UCLA and is board certified in Clinical Molecular Genetics by the American Board of Medical Genetics.
Read more
Steven Flygare
Vice President of Bioinformatics
Board of Directors
John Stuelpnagel, D.V.M.
Co-Founder, Chairman of the Board of Directors
Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.
John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.
Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
John Stuelpnagel, DVM.
Chairman of the Board of Directors
John Stuelpnagel, D.V.M.
Co-Founder, Chairman of the Board of Directors
Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.
John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.
Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Read more
Jim Tananbaum, MD.
Board Member
Martin Reese, Ph.D.
Co-Founder, President, and CEO
A recognized leader in genomics and bioinformatics, Dr. Reese has co-founded and helped build three influential companies in the field – Neomorphic, IDbyDNA, and Fabric Genomics.
At Neomorphic, he developed genome annotation software that enabled Affymetrix’s successful commercialization of microarray technology. He went on to launch IDbyDNA, a spinout from ARUP Laboratories, where he led the creation of the first real-time, web-based pathogen interpretation platform; the company was acquired by Illumina in 2022. Dr. Reese has also played a key role in collaborative efforts to advance genome annotation, contributing to the Berkeley Drosophila Genome Project and developing gene-finding algorithms in support of the Human Genome Project. He holds a master’s degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly awarded by the University of Hohenheim, Germany, and the University of California, Berkeley.
His work has been instrumental in advancing genome annotation, machine learning in genomics, and the broader field of precision medicine.
Martin Reese, PhD.
Co-Founder, President, Board Member, and CEO
Martin Reese, Ph.D.
Co-Founder, President, and CEO
A recognized leader in genomics and bioinformatics, Dr. Reese has co-founded and helped build three influential companies in the field – Neomorphic, IDbyDNA, and Fabric Genomics.
At Neomorphic, he developed genome annotation software that enabled Affymetrix’s successful commercialization of microarray technology. He went on to launch IDbyDNA, a spinout from ARUP Laboratories, where he led the creation of the first real-time, web-based pathogen interpretation platform; the company was acquired by Illumina in 2022. Dr. Reese has also played a key role in collaborative efforts to advance genome annotation, contributing to the Berkeley Drosophila Genome Project and developing gene-finding algorithms in support of the Human Genome Project. He holds a master’s degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly awarded by the University of Hohenheim, Germany, and the University of California, Berkeley.
His work has been instrumental in advancing genome annotation, machine learning in genomics, and the broader field of precision medicine.
Read more
Scientific & Medical Advisory Board
Mark Yandell, PhD.
University of Utah & USTAR Center for Genetic Discovery
Edward Kiruluta
Co-Founder, Fabric Genomics
Paul Flicek, D.Sc.
European Bioinformatics Institute
Gholson Lyon, MD., PhD.
Institute for Basic Research in Developmental Disabilities (IBR)
Thomas Quertermous, MD.
Stanford University Cardiovascular Medicine & VIA Pharmaceuticals
Joshua Schiffman, MD.
University of Utah School of Medicine & Huntsman Cancer Institute
Leroy Hood, M.D., PhD.
Institute for Systems Biology & University of Washington
History
Selected Investors
Discover how Fabric Genomics can help you succeed with NGS testing